[en] Monitoring of gene-expression profiles is assumed to refine tumor characterization of laryngeal squamous cell carcinomas (LSCCs) with a therapeutic perspective. This is especially expected for adhesion/growth-regulatory effectors such as galectins, a class of endogenous lectins. Using computer-assisted microscopy, we investigated the prognostic value contributed by the quantitative determination of the immunohistochemical levels of expression of galectin-1, -3 and -7 in a series of 62 LSCCs including 42 low- and 20 high-stage LSCCs. As galectin-1 may have a key role leading to a tumor escape from immune surveillance, we also investigated whether or not the level of galectin-1 expression correlated with lymphocyte infiltration in LSCCs. The immunohistochemical determination of expression of galectin-1 is of prognostic value in human squamous laryngeal cancers. LSCCs that display high levels of galectin-1 have worse prognoses than laryngeal cancers with low levels of galectin-1 expression. Elevation of galectin-1 levels in laryngeal cancers can contribute to the process of tumor immune escape by killing the activated T-cells and other protumoral activities such as promoting motility or activity of oncogenic H-Ras proteins. The quantitative determination of galectin-1 in LSCCs is an independent prognostic marker when opposed to TNM staging. It has the potential to identify patients unlikely to benefit from T-cell-mediated immunotherapy, although the definitive effector function from its pro- and antitumoral activity profile has not been delineated.
Disciplines :
Immunology & infectious disease Oncology
Author, co-author :
Saussez, Sven ; Université de Mons > Faculté de Médecine et de Pharmacie > Anatomie humaine et Oncologie expérimentale
Gabius H-J, Siebert H-C, André S, Jiménez-Barbero J and Rüdiger H: Chemical biology of the sugar code. Chem Biol Chem 5: 740-764, 2004.
Villalobo A, Nogales-González A and Gabius HJ: A guide to signalling pathways connecting protein-glycan interaction with the emerging versatile effector functionality of mammalian lectins. Trends Glycosci Glycotechnol 18: 1-37, 2006. (Pubitemid 43723385)
Choufani G, Nagy N, Saussez S, et al: The levels of expression of galectin-1, galectin-3, and the Thomsen-Friedenreich antigen and their binding sites decrease as clinical aggressiveness increases in head and neck cancers. Cancer 86: 2353-2363, 1999.
Delorge S, Saussez S, Pelc K, et al: Correlation of galectin-3/galectin- 3-binding sites with low differentiation status in head and neck squamous cell carcinomas. Otolaryngol Head Neck Surg 122: 834-841, 2000.
Paleri V, Pearson JP, Bulmer D, Jeannon JP, Wight RG and Wilson JA: Expression of mucin gene products in laryngeal squamous cancer. Otolaryngol Head Neck Surg 131: 84-88, 2004.
Danguy A, Camby I and Kiss R: Galectins and cancer. Biochim Biophys Acta 1572: 285-293, 2002.
Lahm H, André S, Hoeflich A, et al: Tumor galectinology: insights into a complex network of a family of endogenous lectins. Glycoconj J 20: 227-238, 2004.
Liu FT and Rabinovich GA: Galectins as modulators of tumour progression. Nat Rev Cancer 5: 29-41, 2005.
Piantelli M, Iacobelli S, Almadori G, et al: Lack of expression of galectin-3 is associated with a poor outcome in node-negative patients with laryngeal squamous-cell carcinoma. J Clin Oncol 20: 3850-3856, 2002.
Plzak J, Betka J, Smetana K Jr, et al: Galectin-3 - an emerging prognostic indicator in advanced head and neck carcinoma. Eur J Cancer 40: 2324-2330, 2004.
Danguy A, Rorive S, Decaestecker C, et al: Immunohistochemical profile of galectin-8 expression in benign and malignant tumors of epithelial, mesenchymatous and adipous origins, and of the nervous system. Histol Histopathol 16: 861-868, 2001.
Saussez S, Cucu DR, Decaestecker C, et al: Galectin-7 (p53-induced gene-1): a new prognostic predictor of recurrence and survival in stage IV hypopharyngeal cancer. Ann Surg Oncol 13: 999-1009, 2006.
Saussez S and Kiss R: Galectin-7. Cell Mol Life Sci 63: 686-697, 2006.
Le QT, Shi G, Cao H, et al: Galectin-1: a link between tumor hypoxia and tumor immune privilege. J Clin Oncol 23: 1-10, 2005.
Rubinstein N, Alvarez M, Zwirner NW, et al: Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection: a potential mechanism of tumor-immune privilege. Cancer Cell 5: 241-251, 2004.
Camby I, Le Mercier M, Lefranc F and Kiss R: Galectin-1: A small protein with major functions. Glycobiology 16: 137-157, 2006. (Pubitemid 44530693)
Hyams VJ, Batsakis JG and Michaels L (eds): Tumors of the upper respiratory tract and ear. In: Atlas of Tumor Pathology. Armed Forces Institute of Pathology, Washington DC, 1988.
Decaestecker C, Camby I, Remmelink M, et al: Decision tree induction: a useful tool for assisted diagnosis and prognosis in tumor pathology. Lab Invest 76: 799-808, 1997.
Young MR: Trials and tribulations of immunotherapy as a treatment option for patients with squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 53: 375-382, 2004. (Pubitemid 38657250)
Strome SE and Chen L: Costimulation-based immunotherapy for head and neck cancer. Curr Treat Opt Oncol 5: 27-33, 2004. (Pubitemid 38906622)
Ferris RL, Hunt JL and Ferrone S: Human leukocyte antigen (HLA) class I defects in head and neck cancer: molecular mechanisms and clinical significance. Immunol Res 33: 113-133, 2005.
Albers A, Abe K, Hunt J, et al: Antitumor activity of human papillomavirus type 16 E7-specific T-cells against virally infected squamous cell carcinoma of the head and neck. Cancer Res 65: 11146-11155, 2005.
Lopez-Albaitero A, Nayak JV, Ogino T, et al: Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL. J Immunol 176: 3402-3409, 2006.
Hathaway B, Landsittel DP, Gooding W, et al: Multiplexed analysis of serum cytokines as biomarkers in squamous cell carcinoma of the head and neck patients. Laryngoscope 115: 522-527, 2005.
Whiteside TL: Immunobiology of head and neck cancer. Cancer Metast Rev 24: 95-105, 2005.
Ferris RL: Progress in head and neck cancer immunotherapy: can tolerance and immune suppression be reversed? ORL J Otorinolaryngol Relat Spec 66: 332-340, 2004.
Choi P and Chen C: Genetic expression profiles and biologic pathway alterations in head and neck squamous cell carcinoma. Cancer 104: 1113-1128, 2005. (Pubitemid 41278946)
Reichert TE, Rabinowich H, Johnson JT and Whiteside TL: Mechanisms responsible for signaling and functional defects. J Immunother 21: 295-306, 1998.
Dasgupta S, Bhattacharya-Chatterjee M, O'Malley BW Jr and Chatterjee SK: Recombinant vaccinia virus expressing interleukin-2 invokes anti-tumor cellular immunity in an orthotopic murine model of head and neck squamous cell carcinoma. Mol Ther 13: 183-193, 2006.
Levi G, Tarrab-Hazdai R and Teichberg VI: Prevention and therapy with electrolectin of experimental autoimmune myasthenia gravis in rabbits. Eur J Immunol 13: 500-507, 1983.
Goldstone SD and Lavin MF: Isolation of a cDNA clone, encoding a human β-galactoside-binding protein, overexpressed during glucocorticoid-induced cell death. Biochem Biophys Res Commun 178: 746-750, 1991.
Yang RY, Hsu DK and Liu FT: Expression of galectin-3 modulates T-cell growth and apoptosis. Proc Natl Acad Sci USA 93: 6737-6742, 1996.
Zubieta MR, Furman D, Barrio M, Bravo AI, Domenichini E and Mordoh J: Galectin-3 expression correlates with apoptosis of tumor-associated lymphocytes in human melanoma biopsies. Am J Pathol 168: 1666-1675, 2006.
He J and Baum L: Presentation of galectin-1 by extracellular matrix triggers T-cell death. J Biol Chem 279: 4705-4712, 2004.
